Judging how a burn will heal is one of the harder calls in acute care. Wounds that look superficial can deepen over days, and the decision to excise and graft often hinges on a clinician’s read of tissue that has not yet declared itself. On May 21, 2026, the FDA granted SpectralMD a Direct De Novo authorization for the DeepView AI System, a device meant to add a quantified data point to that call.

The company positions DeepView as a clinical decision-support adjunct: a tool that “provides clinicians with” a healing-potential assessment, intended to inform rather than replace the clinician’s own burn-wound assessment and any decision to excise or graft. The device pairs multispectral imaging with a proprietary algorithm to assess healing potential, flagging areas judged unlikely to heal within 21 days — wounds that, in the company’s words, “may require significant medical intervention.” The openFDA record lists product code SHY under a Direct De Novo pathway, the route the agency uses to classify novel low-to-moderate-risk devices that have no existing predicate.

A new device class, at the bedside

Because it was granted through the De Novo pathway, the authorization establishes a new device classification rather than matching an existing one. Under the FDA’s general De Novo framework, a granted device can subsequently serve as a predicate for future 510(k) submissions — though the openFDA record for DeepView itself makes no statement about future predicate use.

The DeepView System is intended for use in burn care in various settings, including burn centers, trauma centers, and emergency departments.

Per the company, image capture takes about 0.2 seconds and AI classification 20 to 25 seconds, with the model trained on a database it describes as more than 340 billion pixels of burn-wound imagery.

One caveat for readers: the openFDA record does not yet publish the device’s decision summary, and the company’s announcement reports no sensitivity, specificity, or comparator-against-clinician figures. As a result, the device’s standalone accuracy in flagging non-healing burn areas cannot be independently assessed from the primary record. Until the FDA’s summary posts, the pivotal-performance numbers behind this authorization remain unstated — and current clinical practice should not change on the basis of this authorization alone.